pressure -those with baseline >90 reduced from an average of 93 to 80; a 10-point average reduction in total cholesterol (t=-1.13, DF=17, p=0.27), and 50-point average reduction in triglycerides (t=-1.29, DF=17, p=0.21). A continued decrease was observed for A1C, weight, and triglycerides in the first active intervention group 16-weeks post-completion, suggesting sustainability of gains made during the intervention. Discussion: There is a pressing need to address the morbidity and premature mortality related to modifiable health behaviors in this underserved population, yet individuals with SMI and diabetes are much less likely to be identified or to receive recommended diabetes care and monitoring. We hope to further establish and refine a standard of care diabetes education curriculum, tailored for individuals with SMI, a population with high prevalence of diabetes but low rates of diabetes diagnosis, education, and treatment.
pressure -those with baseline >90 reduced from an average of 93 to 80; a 10-point average reduction in total cholesterol (t=-1.13, DF=17, p=0.27), and 50-point average reduction in triglycerides (t=-1.29, DF=17, p=0.21). A continued decrease was observed for A1C, weight, and triglycerides in the first active intervention group 16-weeks post-completion, suggesting sustainability of gains made during the intervention. Discussion: There is a pressing need to address the morbidity and premature mortality related to modifiable health behaviors in this underserved population, yet individuals with SMI and diabetes are much less likely to be identified or to receive recommended diabetes care and monitoring. We hope to further establish and refine a standard of care diabetes education curriculum, tailored for individuals with SMI, a population with high prevalence of diabetes but low rates of diabetes diagnosis, education, and treatment. Results from year one demonstrate this program to be easily implementable, well-accepted, socially relevant and effective. Background: Obsessive compulsive symptoms (OCS) commonly occur in the course of schizophrenia. However, reported rates of comorbid obsessive compulsive disorder (OCD) in schizophrenia were highly variable among studies. In addition, influences of OCS on the symptomatology and functioning of schizophrenia have not been fully explored. The aim of this study was to investigate the clinic-based prevalence rate of OCD in schizophrenia patients, and to evaluated clinical correlates of the comorbidity. Methods: Patients with schizophrenia (n=320) were recruited and lifetime clinical characteristics were evaluated comprehensively. Patients having comorbid OCD (OCD group, n=66) and those without OCD (the non-OCD group, n=254) were compared in terms of clinical characteristics and cognitive functioning. Results: OCD was found in 20.6% of the subjects. Earlier age at onset, male gender, and higher level of education were associated with comorbid OCD. In terms of individual symptoms and symptom dimensions, 'anxiety (p=0.009) and 'depression (p=0.001)' were more frequently observed in the OCD group than in the non-OCD group. The prodromal impairment was higher in the non-OCD group (p=0.016). The OCD group showed better performance in working memory domain (p= 0.003), and other cognitive domains did not show any significant group difference. Discussion: The prevalence rate of OCD in the current subjects was within the range of previously reported comorbidity rates in schizophrenia patients from other populations. Association of OCS with anxiety and depressive symptoms seems to be a common finding which was also reported in previous studies of schizophrenia and bipolar disorders. Regarding cognitive functions, inconsistent results including the current report have been generated suggesting heterogeneous developmental mechanisms of OCS in schizophrenia. Comparisons were made between cohorts regarding demographic variables, psychiatric symptoms, tobacco use, body mass index, waist circumference, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, fasting glucose, systolic blood pressure, and diastolic blood pressure. ANCOVA was used for these analyses, with adjustments for age, duration of the disorder, and duration of psychopharmacological treatment. Results: Mean age was significantly higher for cohort 1 (35.1 years vs. 31.2 years, p < .001). There was no statistically significant difference in any of the other demographic variables or symptoms. Among patients with schizophrenia, there was no significant difference in the prevalence of CVD risk factors except from glucose being slightly increased in patients included in cohort 2 (p = .047). Among patients with bipolar disorder, there was a significant reduction in the level of total cholesterol, LDL, systolic, and diastolic blood pressure in cohort 2 (all p values < .01). These differences remained statistically significant after adjusting for age, duration of the disorder, and duration of psychopharmacological treatment. Discussion: Despite major advances in health promotion and disease prevention during the past decade, the level of CVD risk factors has remained high in patients with schizophrenia. While the level of some CVD risk factors improved in patients with bipolar disorder, they are still at increased risk of CVD. Thus, patients with severe mental disorders, especially schizophrenia, do not appear to have benefited from recent health promotion measures. Our findings also highlight the need for more effective interventions to reduce the risk of CVD in individuals with severe mental disorders, which may reduce the gap in life expectancy compared to the general population. 
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